Format

Send to

Choose Destination
Transplant Proc. 2012 Jun;44(5):1362-7. doi: 10.1016/j.transproceed.2012.01.133.

Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.

Author information

1
Department of General and Visceral Surgery, Zentralklinik, Bad Berka, Germany. Daniel.Kaemmerer@zentralklinik.de

Abstract

BACKGROUND:

Osteopenia and osteoporosis are diseases frequently occurring after liver transplantation (OLT).

PURPOSE:

In a prospective study, we have investigated the effect of ibandronate, vitamin D(3), and calcium on the prevention and treatment of posttransplant osteopenia and osteoporosis.

METHODS:

The bone mineral density (BMD) of the lumbar spine (LS) and of the femoral neck (FN) were measured in 74 patients prospectively pre- and post-OLT.

RESULTS:

Postoperatively the study group showed a consistent percentage increase in BMD (g/cm(2)) and a significantly increased BMD after 12 and 24 months in the LS (12 months: 1.05 ± 0.21 g/cm(2); P < .001 24 months: 1.11 ± 0.19 g/cm(2); P < .001) and the FN (12 months: 0.88 ± 0.16 g/cm(2); P < .002 24 months: 0.90 ± 0.15 g/cm(2); P < .001) in comparison with baseline pre-OLT (LS pre-OLT 0.98 ± 0.19 g/cm(2), FN 0.86 ± 0.14 g/cm(2)). The overall bone fracture rate was 5.4% up to 24 months.

CONCLUSION:

Ibandronate once monthly per os significantly increased the BMD in the LS and FN after OLT at 12 and 24 months. The increased BMD limits the risk of fracture.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center